Diurnal Share Discussion Threads

[dandu69] 17/12/2020 13:33

likewise mafia, the 5613 are mine, I see some good buys coming in after too....

[aimmafia] 17/12/2020 13:16

I've taken some more today

[aimmafia] 17/12/2020 13:16

Surely the herd will see the value here..... it's got to pop soon

[royalalbert] 15/12/2020 23:19

Well a few of us seem to be on the same wavelength, must say this is a severely depressed share price at present but the tide will turn.

you have to be in it to win it.

[tburns] 15/12/2020 23:06

Looking to add again tomorrow

[aimmafia] 15/12/2020 21:46

I bought another £2k ish today

[royalalbert] 15/12/2020 16:53

I'm still buying, not many companies have FDA approval for one of their products.

[bamboo2] 15/12/2020 16:26

Bought a few at 48.25

[s34icknote] 15/12/2020 13:23

This and dddd my laggards !!

[aimmafia] 15/12/2020 11:57

Not a buyer in sight. As soon as News drop there will be a huge scramble to get in when it gaps up. Coiled spring here. There must be news due soon.

[cyberbub] 15/12/2020 10:34

I wouldn't bother responding to the provocateurs...

[best1467] 15/12/2020 10:02

Good educated sum up of the situation the only thing I would add is in my opinion the current valuation is around 65/70% below fare value as things stand right now

[hunsen] 15/12/2020 09:18

Glasswala, you comments are wrong and not qualified at all.

“Confidence has gone from this share” – this is wrong, the company has rerated from the high 20’s, low 30’s to the high 40s, low 50s – an increase of 72% pre Alkindi FDA approval. Funds are increasing holdings and one individual fund manager is (mostly out) – it’s a “stock market” and it’s AIM. There currently is no momentum or volume, there is so much action elsewhere at the moment and there is not much to see here.

“Directors prone to giving shares away at a discount” – this is wrong, the company needs funding because it is not yet profitable – you should have done your research before leaping into a share. The Directors have a choice of getting a loan (which attracts interest which must be paid to the lender BEFORE shareholders), OR Directors can go to shareholders and pay that interest in the form of a discount. Shareholders then have the choice to take part or not.
As it happens, the 9% discount on the last placing was quite a premium to where the share currently sits – so the company did very well, and shareholders will hopefully be rewarded in time.

The DNL share price has increased 72%, there is no reason for a further increase before the New Year. There may still be a small stock overhang from a large seller, when this clears the price may increase as MM struggle to buy shares.
Positive news may also drive an increase – the next news will hopefully be approval of Chronocort.

The Directors then need to start delivering on the business plan – so far, they have remained consistent in my view.

ALB

[glasswala] 14/12/2020 13:09

Nearly as both are in the same boat except STX have not done share placing just yet

[weatherman] 14/12/2020 12:53

You said the same about STX. Hmmm?

[glasswala] 14/12/2020 12:21

All confidence has gone from this share. Directors of aim companies are prone to giving away shares at discounted prices even when they have good products and the all important approval from FDA to drive the shares upwards.

[l0ngterm] 11/12/2020 23:54

If you believe in markets then yes and no.

[dandu69] 11/12/2020 19:48

Forgive me for asking what may be a simple question - was the price fall artificial to accommodate a buy order of 70000 at a lower price? Once this has been cleared the price could rise back to the previous level?

[aimmafia] 11/12/2020 17:41

People dumping massive chunks and getting ripped off is hilarious

[best1467] 11/12/2020 15:06

I Think HL did quite an in depth research note and they stated 3 similar Nassdaq quoted companies some without Fda approvals.or EMA and the average valuation was around 220 million

[shrewdmole] 11/12/2020 13:22

actual spread is very tight

[dandu69] 11/12/2020 12:19

Thanks, at least it puts them on the radar of other potential investors reading the article.

[shrewdmole] 11/12/2020 12:12

51.7p for 26k

[bradders51] 11/12/2020 12:00

"Another is Diurnal, a pharmaceutical company developing hormone treatments for rare diseases, such as adrenal insufficiency. It has a £80m valuation versus £450m for American rival Spruce."

Not quite sure why it's mentioned. No talk of DNL doing a 4D is there?